CA1276633C - Imidazo-pyridine derivatives - Google Patents

Imidazo-pyridine derivatives

Info

Publication number
CA1276633C
CA1276633C CA000484263A CA484263A CA1276633C CA 1276633 C CA1276633 C CA 1276633C CA 000484263 A CA000484263 A CA 000484263A CA 484263 A CA484263 A CA 484263A CA 1276633 C CA1276633 C CA 1276633C
Authority
CA
Canada
Prior art keywords
formula
compound
alkyl
carboxy
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000484263A
Other languages
English (en)
French (fr)
Inventor
Leslie J. Browne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of CA1276633C publication Critical patent/CA1276633C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA000484263A 1984-06-20 1985-06-18 Imidazo-pyridine derivatives Expired - Lifetime CA1276633C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/622,421 US4617307A (en) 1984-06-20 1984-06-20 Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US622,421 1984-06-20

Publications (1)

Publication Number Publication Date
CA1276633C true CA1276633C (en) 1990-11-20

Family

ID=24494112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000484263A Expired - Lifetime CA1276633C (en) 1984-06-20 1985-06-18 Imidazo-pyridine derivatives

Country Status (31)

Country Link
US (1) US4617307A (env)
EP (1) EP0165904B1 (env)
JP (1) JPS6112688A (env)
KR (1) KR900008566B1 (env)
AT (1) ATE62415T1 (env)
AU (1) AU589565B2 (env)
BG (7) BG60262B2 (env)
CA (1) CA1276633C (env)
CS (1) CS268672B2 (env)
CY (1) CY1750A (env)
DD (1) DD237510A5 (env)
DE (1) DE3582452D1 (env)
DK (1) DK170302B1 (env)
DZ (1) DZ799A1 (env)
ES (6) ES8702406A1 (env)
FI (1) FI80694C (env)
GR (1) GR851487B (env)
HK (1) HK23494A (env)
HU (1) HU202529B (env)
IE (1) IE58070B1 (env)
IL (1) IL75546A (env)
MA (1) MA20459A1 (env)
MX (1) MX9203369A (env)
NO (1) NO162467C (env)
NZ (1) NZ212483A (env)
PH (1) PH23390A (env)
PL (6) PL145104B1 (env)
PT (1) PT80661B (env)
RO (1) RO92583A (env)
SU (6) SU1433413A3 (env)
ZA (1) ZA854615B (env)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5171858A (en) * 1985-06-05 1992-12-15 Schering A.G. Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
IL83163A (en) * 1986-07-18 1991-06-10 Erba Carlo Spa Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
US5066656A (en) * 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
CA2066369A1 (en) * 1991-04-19 1992-10-20 Alex Elbrecht Control of sex differentiation in fish
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
JPH05176659A (ja) * 1991-04-26 1993-07-20 Merck & Co Inc 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法
AU2356195A (en) * 1994-04-14 1995-11-10 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
AU682947B2 (en) * 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60309887T2 (de) * 2002-07-30 2007-05-16 Novartis Ag Kombination von einem aromatasehemmer mit einem bisphosphonat
CA2494636A1 (en) * 2002-08-07 2004-02-19 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
CA2505752A1 (en) * 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
CA2568165A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
US20080076784A1 (en) * 2004-05-28 2008-03-27 Peter Herold Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
RU2008150752A (ru) * 2006-05-26 2010-07-10 Новартис АГ (CH) Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы
US20090286790A1 (en) 2006-07-20 2009-11-19 Hidetomo Imase Organic compounds
KR20090055595A (ko) * 2006-08-25 2009-06-02 노파르티스 아게 알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PT2404901E (pt) 2007-12-03 2013-08-29 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR086665A1 (es) * 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
IN2014DN06781A (env) * 2012-01-17 2015-05-22 Novartis Ag
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
HUE054248T2 (hu) * 2015-01-29 2021-08-30 Recordati Ag Eljárás kondenzált imidazo-származékok elõállítására
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JP2016074729A (ja) * 2015-12-31 2016-05-12 国立大学法人 千葉大学 イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EP3532056A1 (en) * 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor
WO2018078049A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (env) * 1971-03-15 1976-07-24
FR2449689A1 (fr) * 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
CA1250844A (en) * 1981-06-22 1989-03-07 Neville Ford Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
US4409226A (en) * 1981-10-05 1983-10-11 Schering Corporation Imidazo[1,5-a]pyridines
US4361567A (en) * 1981-10-05 1982-11-30 Schering Corporation Treatment of peptic ulcer disease
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors

Also Published As

Publication number Publication date
FI852399L (fi) 1985-12-21
FI80694B (fi) 1990-03-30
ATE62415T1 (de) 1991-04-15
ES555541A0 (es) 1987-11-16
ES8702406A1 (es) 1987-01-01
NZ212483A (en) 1988-10-28
ES8802155A1 (es) 1988-04-01
ES8801262A1 (es) 1987-12-16
HUT37936A (en) 1986-03-28
PL145105B1 (en) 1988-08-31
SU1443802A3 (ru) 1988-12-07
ES8802049A1 (es) 1988-03-16
GR851487B (env) 1985-11-25
MA20459A1 (fr) 1985-12-31
PL145087B1 (en) 1988-08-31
ES555540A0 (es) 1987-12-16
BG60262B1 (bg) 1994-03-31
NO852474L (no) 1985-12-23
DE3582452D1 (de) 1991-05-16
IL75546A (en) 1990-01-18
PL145348B1 (en) 1988-09-30
ES8802048A1 (es) 1988-03-16
AU589565B2 (en) 1989-10-19
BG60306B2 (bg) 1994-07-25
PL254099A1 (en) 1986-09-09
ZA854615B (en) 1986-02-26
HK23494A (en) 1994-03-25
HU202529B (en) 1991-03-28
BG60262B2 (en) 1994-03-31
ES8800681A1 (es) 1987-11-16
DK170302B1 (da) 1995-07-31
JPS6112688A (ja) 1986-01-21
DD237510A5 (de) 1986-07-16
CS268672B2 (en) 1990-04-11
RO92583A (ro) 1987-11-30
SU1436878A3 (ru) 1988-11-07
EP0165904B1 (de) 1991-04-10
PL145103B1 (en) 1988-08-31
PL145104B1 (en) 1988-08-31
BG60352B2 (bg) 1994-11-30
EP0165904A3 (en) 1987-09-09
MX9203369A (es) 1992-09-01
AU4385785A (en) 1986-01-02
PT80661A (en) 1985-07-01
KR860000299A (ko) 1986-01-27
PH23390A (en) 1989-07-26
SU1433413A3 (ru) 1988-10-23
BG60305B2 (bg) 1994-07-25
JPH047746B2 (env) 1992-02-12
BG60402B2 (bg) 1995-02-28
ES544344A0 (es) 1987-01-01
ES555539A0 (es) 1988-04-01
CS444985A2 (en) 1989-07-12
BG60353B2 (bg) 1994-11-30
NO162467B (no) 1989-09-25
SU1436880A3 (ru) 1988-11-07
IL75546A0 (en) 1985-10-31
IE851520L (en) 1985-12-20
ES555538A0 (es) 1988-03-16
BG60307B2 (en) 1994-07-25
EP0165904A2 (de) 1985-12-27
IE58070B1 (en) 1993-06-30
DK277685A (da) 1985-12-21
US4617307A (en) 1986-10-14
FI852399A0 (fi) 1985-06-17
SU1436879A3 (ru) 1988-11-07
DK277685D0 (da) 1985-06-19
FI80694C (fi) 1990-07-10
KR900008566B1 (ko) 1990-11-24
SU1482530A3 (ru) 1989-05-23
CY1750A (en) 1994-06-03
PL145814B1 (en) 1988-11-30
NO162467C (no) 1990-01-10
PT80661B (en) 1987-05-04
DZ799A1 (fr) 2004-09-13
ES555542A0 (es) 1988-03-16

Similar Documents

Publication Publication Date Title
KR900008566B1 (ko) 치환된 바이시클릭 화합물의 제조방법
EP2158201B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
HUP9903009A2 (hu) Szubsztituált indazolszármazékok és IV típusú foszfodiészteráz (PDE) és tumornekrózis faktor (TNF) inhibítorokként történő alkalmazásuk
CZ2001485A3 (cs) Substituované 1,8- naftyridin-4(1H)-ony, farmaceutické kompozice na jejich bázi, způsob léčení a způsob inhibice fosfodiesterasy 4
CZ349298A3 (cs) Deriváty indazolu, farmaceutické kompozice, meziprodukty a způsoby léčení
FR2698873A1 (fr) Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
EP0760812A1 (en) Pharmaceutical diketopiperazine compounds
CZ284896A3 (en) Novel hydroxypyridinones, process of their preparation and pharmaceutical composition in which such hydroxypyridinones are comprised
KR100326790B1 (ko) 신규한피롤로카바졸
KR100293867B1 (ko) 아미노스틸바졸유도체및의약
JPH0971586A (ja) 新規な二環性縮合イミダゾール誘導体
EP2158194B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
US20020156064A1 (en) Compounds and their use as PDE inhibitors
EP0920319A1 (en) Antagonists of gonadotropin releasing hormone
CA2275351C (fr) Nouveaux analogues de la camptothecine, leur application comme medicaments et les compositions pharmaceutiques les contenant
US20260092066A1 (en) Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
HUP0302405A2 (hu) Új benzofuránszármazékok
US6150522A (en) Antagonists of gonadotropin releasing hormone
EP0328111A2 (en) Cancer cell metastasis inhibitors
JPS59118785A (ja) イミダゾ〔１，５−ａ〕ピリジン誘導体及びその製造方法，並びに該誘導体を含有する医薬
IE46385B1 (en) N-9, 10-dihydrolysergyl-m-aminobenzinc acid amides and related compounds
WO1992021647A1 (en) Carbocyclic and heterocyclic hiv protease inhibitors
JP2000511897A (ja) ２０（ｓ）カンプトテシンの新規な水溶性類似体
IE921936A1 (en) Bicyclic-substituted vinylimidazoles, -triazoles and¹-tetrazoles
EP0377532B1 (en) Thioformamide derivatives

Legal Events

Date Code Title Description
MKEX Expiry